Login to Your Account

Genzyme's Myozyme Now On File, Seeking Priority Review

By Aaron Lorenzo

Monday, August 1, 2005
As expected, Genzyme Corp. filed for FDA approval of Myozyme (alglucosidase alfa) concurrent with a report that the enzyme-replacement therapy met its primary endpoint in a pivotal study of infantile-onset Pompe disease patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription